PremiumThe FlySynaptogenix announces FDA approved IND application for Bryostatin-1 Synaptogenix CEO Dr. Tuchman’s Tenure Extended Through 2024 Synaptogenix regains compliance with Nasdaq listing rules PremiumThe FlySynaptogenix’s Bryostatin-1 in Alzheimer’s featured in peer-reviewed publication Synaptogenix announces findings from independent study on Bryostatin-1 Synaptogenix announces agreement with Cleveland Clinic for Bryostatin-1 trial PremiumThe FlySynaptogenix announces results from Phase 2 clinical trial of Bryostatin-1 
